Baseline characters of patients
| Variables | All patients | Training cohort | Validation cohort | P values |
| Number of patients (%) | 398 | 266 (66.8%) | 132 (33.2%) | – |
| Age (years) | 38.6±12.1 | 38.8±12.1 | 38.1±12.1 | 0.997 |
| Gender (male) | 265 (66.6%) | 175 (65.8%) | 90 (68.2%) | 0.634 |
| BMI (kg/m2) | 22.8±3.26 | 22.8±3.3 | 22.8±3.2 | 0.951 |
| FBG (g/L) | 5.2±1.2 | 5.2±1.1 | 5.1±1.4 | 0.860 |
| PLT (109/L) | 177.8±64.0 | 175.0±61.2 | 183.4±69.1 | 0.218 |
| AST (IU/L) | 43.9±46.5 | 43.5±42.2 | 44.6±54.5 | 0.832 |
| ALT (IU/L) | 54.9±53.9 | 54.9±57.5 | 54.9±46.0 | 0.997 |
| GGT (IU/L) | 47.5±62.1 | 49.2±64.6 | 43.9±56.7 | 0.428 |
| TB (µmol/L) | 15.9±8.6 | 16.0±9.2 | 15.7±7.3 | 0.724 |
| DB (µmol/L) | 5.3±5.2 | 5.6±5.9 | 4.7±2.9 | 0.113 |
| IB (µmol/L) | 10.9±5.8 | 10.8±6.1 | 11.0±5.2 | 0.727 |
| ALP (IU/L) | 83.8±33.5 | 82.1±32,5 | 87.5±35.2 | 0.131 |
| ALB (g/L) | 44.8±26.5 | 43.4±8.5 | 47.6±44.4 | 0.134 |
| PT (%) | 90.7±13.1 | 90.9±13.4 | 90.1±12.3 | 0.557 |
| HBV status | ||||
| HBeAg (+/−) | 150/248 | 96/170 | 54/78 | 0.428 |
| HBeAg (+/−) CI | 66/143 | 45/97 | 21/46 | 0.913 |
| Fibrosis stages | ||||
| F0-1 | 65 (16.3%) | 43 (16.1%) | 22 (16.7%) | 0.993 |
| F2 | 109 (27.4%) | 72 (27.1%) | 37 (28.0%) | 0.944 |
| F3 | 126 (31.7%) | 85 (32.0%) | 41 (31.1%) | 0.946 |
| F4 | 98 (24.6%) | 66 (24.8%) | 32 (24.2%) | 0.994 |
| Inflammation grades | ||||
| A0 | 1 (0.3%) | 1 (0.4%) | 0 (0%) | – |
| A1 | 137 (34.4%) | 84 (31.6%) | 53 (40.2%) | 0.132 |
| A2 | 148 (37.2%) | 106 (39.8%) | 42 (31.8%) | 0.149 |
| A3 | 112 (28.1%) | 75 (28.2%) | 37 (28.0%) | 0.939 |
Qualitative variables are in n (%), and quantitative variables are in mean±SD, when appropriate.
HBV status was categorised according to 2017 European Association for the Study of the Liver (EASL) guideline.
P values were calculated between the training and validation cohorts.
ALB, albumin; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; DB, direct bilirubin; FBG, fasting blood glucose; GGT, gamma-glutamyl transpeptidase; HBeAg, hepatitis Be antigen; HBeAg (+/−) CI, hepatitis Be antigen (+/−) chronic infection; IB, indirect bilirubin; PLT, platelet count; PT, prothrombin activity; TB, total bilirubin.